Monkeypox – European Clinical Trials Information Network

Study of Different Doses of MVA-BN Vaccine Booster for Adults with Mpox: Comparing Standard and Reduced Doses

Wed, 29 Apr 2026 15:05:27 +0000

This study focuses on mpox (formerly known as monkeypox) and investigates the effectiveness of booster vaccinations using IMVANEX, which contains Modified Vaccinia Ankara virus. The vaccine is given as an injection under the skin (subcutaneous injection), and the study compares two different doses of the same vaccine – a standard dose and a reduced dose.

The purpose of this research is to determine if a smaller dose of the vaccine can provide the same level of protection against mpox virus as the standard dose when given as a booster shot. The vaccine contains a modified form of the vaccinia virus that has been altered to be safe while still helping the body develop protection against mpox.

During the study, participants will receive one booster dose of the vaccine and will be monitored for six months. The study will measure the body’s immune response by checking for protective substances (antibodies) in the blood. Healthcare providers will also track any reactions or side effects that may occur after vaccination. Blood samples will be collected at specific times to measure how well the vaccine is working.

Study on the Effectiveness of Modified Vaccinia Ankara Vaccine in Preventing Mpox Infection in Adults

Wed, 29 Apr 2026 14:47:56 +0000

This clinical trial is focused on studying the prevention of Mpox infection, which is a disease caused by a virus similar to the one that causes smallpox. The study will use a vaccine called IMVANEX, which is a suspension for injection containing a live virus known as Modified Vaccinia Ankara – Bavarian Nordic Live Virus. This vaccine is designed to help the body build protection against the Mpox virus.

The purpose of the study is to understand how the body’s immune response, specifically the antibodies that fight the virus, changes over time after receiving the vaccine. Participants in the study will receive either one or two doses of the vaccine. The study will monitor the levels of these antibodies at different times, up to 48 weeks after vaccination. This will help researchers learn more about how long the vaccine’s protection lasts and what factors might influence this.

Throughout the study, participants will have regular check-ups to measure the presence of antibodies and to ensure their well-being. The study will also look at the vaccine’s ability to neutralize the virus in laboratory settings and check for any other infections that might occur during the study period. This research aims to provide valuable information on the effectiveness of the IMVANEX vaccine in preventing Mpox infection.

Study on Monkeypox Virus Disease: Effects of Tecovirimat in Patients with and without Antiviral Treatment

Wed, 29 Apr 2026 14:25:15 +0000

This clinical trial is focused on studying the disease known as Monkeypox virus disease, which is sometimes referred to as mpox. The study involves a treatment using a medication called Tecovirimat, which is taken in the form of 200 mg hard capsules. The purpose of the study is to observe the clinical outcomes in patients with mpox who are treated with tecovirimat or other antiviral drugs, as well as those who are not treated with these medications.

Participants in the study will be monitored over a period of time to see how their condition progresses. The study will look at how quickly the skin lesions caused by the mpox virus heal, starting from the date of a positive test or the beginning of treatment, and continuing for up to 14 days. The study will also assess the overall health status of participants on days 14 and 28, and check for any signs of the disease returning on days 60 and 180. Additionally, the study will monitor the levels of mpox virus DNA in the throat, blood, and lesion swabs at various points during the study.

For those receiving tecovirimat or other antiviral treatments, the study will track any serious side effects or unexpected reactions within 28 days of starting the study. The study will also consider the outcomes for pregnant women who are participating. This research aims to provide valuable information on the effectiveness and safety of tecovirimat and other antiviral treatments for mpox.

Study on Tecovirimat for Treating Monkeypox in Patients with Confirmed Infection

Wed, 29 Apr 2026 14:24:59 +0000

This clinical trial is focused on studying the disease known as monkeypox, which is a viral infection that can cause skin and mucosal lesions. The trial will evaluate the effectiveness of a treatment using a medication called Tecovirimat, which is taken in the form of 200 mg hard capsules. Participants in the study will be divided into two groups: one group will receive the Tecovirimat treatment, while the other group will receive a placebo, which looks like the Tecovirimat capsules but does not contain the active substance.

The purpose of the study is to gather evidence on how well the treatment works by observing the time it takes for the skin and mucosal lesions to heal completely. The study will follow participants over a period of time to monitor the healing process of their lesions. Participants will be assessed at various points, including days 7, 14, 21, and 28, to check the status of their lesions and any symptoms they may experience, such as fatigue, nausea, or pain. The study will also look at the quality of life of participants and any changes they experience during the trial.

Throughout the study, the occurrence of a negative test for monkeypox will be checked, and any scars or skin discoloration will be assessed. The trial will also monitor for any complications, hospital admissions, or deaths that may occur. The study aims to provide valuable information on the effectiveness of Tecovirimat in treating monkeypox and improving the quality of life for those affected by the disease.